PhRMA conferees fault industry for poor messaging

Share this article:
Chris Viehbacher
Chris Viehbacher
PhRMA's annual meeting in Boston was full of talk about how scientific advances are pushing the boundaries of medicine's potential, but the mood was woe-is-me as members pondered their industry's poor public reputation.

The key complaint was that the industry has been waiting for praise rather than trumpeting its value.

“We need to hammer home that we support over four million jobs," said Sanofi CEO and outgoing PhRMA chair Chris Viehbacher. "We are thought of as healthcare, but we create human capital,” he said, adding that “we need to be sure wherever we go that what we stand for is better science."

Viehbacher said the industry has a place in conversations about health literacy and conveying the importance of taking meds as prescribed because it's a space where the industry can leverage its expertise regarding “better management of chronic disease, better adherence to medication."

"We have the ability to participate in that debate,” said Viehbacher. "We cannot say that's not our problem.

He said inserting the industry in these patient-centered conversations will show that it has a place in battling rising healthcare costs, for which he says the companies are unfairly blamed. They do too little messaging to counter that misperception, he added.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...